Skip to content

Bridging the Innovation Gap in the Treatment of Mild to Moderate Dermatological Diseases

Time: 3:35 pm
day: Day One

Details:

• Addressing the unmet need in topical drug development towards a large patient population with mild to moderate dermatological diseases, still primarily using topical steroids
• Updating on SNA-120 (TrkA inhibitor) – SNA-120, a novel approach to the treatment of psoriasis, targeting NGF/TrkA and neurogenic inflammation
– The important role of nerves & neuropeptides in psoriasis
– Itch as a proxy clinical biomarker for high NGF/TrkA expression in psoriasis
– A novel non-steroidal approach in the treatment of psoriasis and associated itch targeting the NGF/TrkA pathway

Speakers: